Understanding of progression to antiretroviral therapy (ART) eligibility and associated factors remains limited. The objectives of this analysis were to determine the time to ART eligibility and to explore factors associated with disease progression in adults with early HIV infection.
Introduction
Studies in different settings have estimated the time from HIV-1 seroconversion to reaching a CD4 cell count threshold of 350 cells/μl for treatment eligibility to be 4-5 years [2, 3] . Virological and immunological factors associated with disease progression have been well characterized [4] , but the impact of sociodemographic and psycho-behavioural factors on disease progression and time to ART eligibility has been studied less extensively, particularly in sub-Saharan Africa [5, 6] . Understanding the influence of these factors on HIV disease progression is important to inform pre-ART care and monitoring strategies, and for policy decisions concerning the timing of ART initiation and the use of ART for prevention. There are few data on time to ART eligibility in those who present in early HIV infection, although increasing numbers of people are diagnosed and enter care at higher CD4 cell counts [7] . We used data from a longitudinal study investigating the impact of ART on the partnerships and sexual behaviour of HIV-infected individuals to explore factors associated with disease progression in adults in the early stages of HIV infection [8] .
Methods
People can access HIV counselling and testing at any primary health care (PHC) clinic in the Hlabisa sub-district Adult (≥ 18 years old) HIV-infected men and nonpregnant women accessing care at three of the PHC clinics and resident within the Africa Centre Demographic Surveillance Area were potentially eligible for inclusion in the parent study and were approached for recruitment if their CD4 cell count was < 200 cells/μl or > 500 cells/μl [8] . Individuals were asked to consent separately to linkage of their study data with routine clinical data collected in the HIV programme, specifically clinic attendance history and laboratory test results, and with the Africa Centre Demographic Information System (ACDIS) database for their residential history. Sociodemographic, behavioural and partnership-level data were collected at enrolment [10] . Study participants were interviewed 6-monthly during routine clinic visits, or where necessary during home visits or by phone.
The study was approved by the ethics committees of the University of KwaZulu-Natal (BF083/08), the London School of Hygiene and Tropical Medicine (5413), and the KwaZulu-Natal Department of Health.
Individuals with CD4 cell count > 500 cells/μl at enrolment were advised to return 6-monthly for repeat clinical assessment and CD4 cell count measurement; those with at least one post-enrolment CD4 cell count result contributed to the analyses. Characteristics at enrolment for individuals included in the analyses were compared with those for individuals who were not using χ 2 tests for categorical variables and Wilcoxon rank sum tests for continuous variables.
Study recruitment started in January 2009, with follow-up for 36 months maximum. While many individuals continued to access care from the local HIV programme, with additional post-study CD4 cell count results, only results from tests conducted during study follow-up were included in this analysis.
Individuals who initiated ART for clinical reasons were also considered ART-eligible; their ART initiation date was their eligibility date. ART initiation date was documented during follow-up or by linkage to the HIV programme database. Follow-up time for individuals not meeting ART eligibility criteria was censored at the last CD4 cell count test date.
Time from study enrolment to ART eligibility, defined as CD4 cell count < 350 cells/μl, was estimated by Kaplan − Meier survival analysis. Associations between the time to ART eligibility and sociodemographic and behavioural factors at enrolment, including ART knowledge, social capital, social support, relationship characteristics, and internalized HIV stigma (composite score from adapted scales), were initially explored using univariable Cox models [8, 10] . We considered all variables that were significant at univariable level (p value < 0.05) for the multivariable model. Given previously reported faster disease progression in men, we explored an interaction term between CD4 cell count and sex in the final multivariable model. CD4 cell count was included in the model as a set of binary indicators representing quartiles of the baseline distribution: ≤ 559, 560-632, 633-768 and > 768 cells/μl. The interaction between CD4 cell count and sex was tested using seven binary indicators to represent the eight possible categories. A likelihood ratio test of this interaction was performed and the results compared to a χ 2 distribution with three degrees of freedom. The final model was tested to check that the proportional hazards assumption held.
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Results
Overall, 247 adults had been enrolled by March 2011; 41 (17%) had no post-enrolment CD4 cell count result and did not contribute to the analyses. These 41 did not differ from the 206 included by age (P = 0.46), sex (P = 0.56) and enrolment CD4 cell count (P = 0.69). Thus, 206 adults (14% male; median age 34 years) contributed 381 years of follow-up [median 24 months; interquartile range (IQR) 15-30 months] (Table 1) , with a median number of CD4 cell count measurements of 3 (IQR 2-4). CD4 cell count measurement number was not significantly associated with any factor included in the final model (data not shown). Overall, 79 (38%) participants became eligible for ART: 75 by CD4 cell count criteria (< 350 cells/μl) and four for clinical reasons. Among these 79, 41 (52%) started ART during study follow-up. Based on a CD4 cell count of 500 cells/μl, 129 (63%) would have become eligible for ART.
Univariably, the following were significantly associated with increased hazard of becoming ART-eligible: male sex [hazard ratio (HR) 3. taking nutritional supplements between enrolment and 6 months (HR 2.06; 95% CI 1.11-3.83; P = 0.022) and ever use of recreational drugs (HR 2.35; 95% CI 1.08-5.15; P = 0.03) ( Table 2) . Once adjusted for sex, the number of lifetime partners and ever use of recreational drugs were no longer significant. Reported ever alcohol use was 35% among female patients and 89% among male patients (P < 0.001), and reported use in the first 6 months of follow-up was 4% and 43% among female and male patients, respectively. Neither ever or current alcohol use was associated with time to ART eligibility. The limited number of female current drinkers hindered exploration of associations between time to ART eligibility and alcohol use in a model including male sex.
Multivariably, lower CD4 cell count at enrolment, being male, residing in a household with food shortage in the last year, and nutritional supplement use remained significantly associated with increased hazard of meeting ART eligibility criteria (Table 2 ). There was no evidence of an Median time to CD4 cell count < 500 cells/μl for men was 8.3 months (95% CI 6.0-18.6 months) and for women it was 17.8 months (95% CI 15.9-19.7 months).
Discussion
Just over one in three HIV-infected adults enrolled in HIV care at an early stage became eligible for ART at a CD4 cell count < 350 cells/μl. In these HIV-infected people with an initial CD4 count > 500 cells/μl, progression to ART eligibility was associated with lower baseline CD4 cell count, male sex, household food insecurity and the personal use of nutritional supplements. The study population was predominantly female, consistent with previously reported data [9, 13, 14] , and probably reflecting higher population-level CD4 cell counts among women [15] and the different entry points into HIV care. Previous work did not find any association between sex and disease progression pre-ART initiation [4]; however, mortality after ART initiation is consistently higher in men [16] . Men enrolled in our study may be incompletely representative of all men with CD4 cell counts > 500 cells/μl as a consequence of unmeasured clinical characteristics, but our finding that time to ART eligibility was significantly shorter for men highlights the need to develop male-oriented strategies throughout HIV care [17, 18] . Current guidelines recommend ART for all pregnant females and individuals with TB disease, regardless of CD4 cell count, but this was not the case throughout the study period. We did not estimate the effect this might have on overall progression to eligibility, although the estimates would be unlikely to change substantially as the majority of TB cases and pregnancies are associated with CD4 cell counts < 350 cells/μl in South Africa [19, 20] .
Use of nutritional supplements in the first 6 months of follow-up may indicate poorer nutritional state and low body mass index (BMI); similarly, the association with self-reported household lack of food could also reflect a link between food insecurity, malnutrition and disease progression. Other household socioeconomic status indicators were not associated with time to ART eligibility, suggesting a specific role of nutrition [21] . However, there is no clear evidence that macronutrient or micronutrient supplementation delays HIV disease progression in nonpregnant adults [22] [23] [24] . The complex interplay between HIV and nutrition means that determining cause and effect relationships is difficult; this was certainly the case in this analysis, given the study design and the lack of clinical indicators such as BMI [25] . There was no evidence of an association between disease progression and any behavioural factors (including ART knowledge, social capital, social support, relationship characteristics, and internalized stigma). Therefore, while interventions to address these issues may have merit, they should not be expected to delay disease progression.
Our results are similar to those from a smaller study, also from KwaZulu-Natal, of female patients monitored from [27, 28] , international and national guidelines now recommend initiation of ART if the CD4 cell count is < 500 cells/μl [29, 30] . Whereas immediate ART may improve survival in adults with CD4 cell counts > 500 cells/μl, this benefit might be reversed by potentially high rates of treatment failure or disengagement from care [31] ; the latter may be more likely as programmes expand [32] [33] [34] . In this population, around one in four adults now present for HIV care with a CD4 cell count > 500 cells/μl [7] ; our finding that most of such adults had not become eligible during follow-up is consistent with regional natural history data [35] and suggests that risks of treatment failure and costs of treatment could be deferred for a considerable time. However, whether or not this changes the overall individual benefit/risk ratio and whether there are additional population-level risks or benefits remain to be seen [36, 37] . Our data would suggest that many individuals will become eligible within one or two visits in pre-ART care, especially if visits are less frequent than the recommended 6 months [13] . Education and counselling should emphasize the importance of retention in care to all patients not yet requiring ART. Focused messages and systems may be required to enable retention of men, who may have faster disease progression and poorer retention in pre-ART care [13, 38] .
